05.03.19

Allergan to Present Two Podium Presentations on Bimatoprost Sustained-Release (SR) at ASCRS

Source: Allergan

Allergan will present new data for its investigational implant, Bimatoprost SR, and a late-breaking analysis on its subconjunctival gelatin implant, XEN Gel Stent, at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego, from May 3– 7. During a podium session on Sunday, May 5, Allergan will present an analysis exploring the treatment duration of Bimatoprost SR and a separate presentation on the biodegradation data from a phase 1/2 study. These presentations follow data that was presented at the most recent Association for Research in Vision and Ophthalmology (ARVO) annual meeting.

“The data presented at ASCRS underscores our commitment to turning innovative research into meaningful treatment options that improve the experience for patients with open-angle glaucoma or ocular hypertension,” Yehia Hashad, MD, Senior Vice President, Head of Global Clinical Development, Allergan, said in a company news release. “Building upon the intraocular pressure lowering control of Bimatoprost SR seen in our phase 3 trials, this new data provides insights into how the duration of treatment and rate of biodegradation may factor into the medicine’s overall effectiveness.”

Bimatoprost SR is a first-in-class sustained-release, biodegradable implant being evaluated for the reduction of IOP in patients with open-angle glaucoma or ocular hypertension. Topline phase 3 efficacy and safety results from ongoing studies will be presented at a congress later this year. Allergan anticipates submitting a new drug application (NDA) to the FDA in the second half of 2019.

The data analysis from a phase 1/2, 24-month, prospective, multicenter, dose-ranging study of 75 open-angle glaucoma patients evaluated the rate of biodegradation on the implant and the impact on the IOP-lowering effect of Bimatoprost SR. A second analysis of data from the phase 1/2 and phase 3 clinical studies assessed the duration of IOP control based on the time after administration of Bimatoprost SR without the use of other IOP-lowering therapies.

Allergan will present two abstracts as podium presentations and will have one late-breaking abstract (all noted in local Pacific Time):

Podium Presentations:

  • Duration of Effect of Intracameral Bimatoprost Sustained-Release Implant (Bimatoprost SR) in phase 1/2 and phase 3 Clinical Studies
    • Authors: Weinreb RN et al
    • Date and Time: Sunday, May 5, 3:27 – 3:32 PM
    • Location: SDCC – Upper Level, Room 7A
    • Session Title: SPS-217 Measurements and Medications
  • Biodegradation of Intracameral Bimatoprost Sustained-Release Implant (Bimatoprost SR) in a 24-Month, phase 1/2 Study in Glaucoma Patients
    • Authors: Craven ER et al
    • Date and Time: Sunday, May 5, 3:32 – 3:37 PM
    • Location: SDCC – Upper Level, Room 7A
    • Session Title: SPS-217 Measurements and Medications
  • Effectiveness and Safety of the Subconjunctival Gelatin Implant Alone or Combined with Cataract Surgery
    • Authors: Hengerer FH et al
    • Date and Time: Sunday, May 5, 2:08 – 2:13 PM
    • Location: SDCC – Upper Level, Room 7B
    • Session Title: SPS-212 MIGS

 

 

 

Related Content